PSG’s chief data and analytics officer Libby Johnson and VP in specialty clinical consulting Renee Rayburg
Specialty drug market jumps, driven by new users — not higher price tags — and more biosimilar uptake
The prescription specialty drug market is rebounding from a pandemic dip which isn’t surprising, but what’s driving it may be. A recent annual spending and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.